Skip to main content
Premium Trial:

Request an Annual Quote

Jean-Pierre Wery, Lauri Caviston, Samraat Raha, Ann Reynolds

Premium

The Indiana Centers for Applied Protein Sciences announced last week the appointment of Jean-Pierre Wery as chief scientific officer, and Lauri Caviston as vice president of business development in sales and marketing.

Prior to joining INCAPS, Wery worked at Vitae Pharmaceuticals as vice president of computational drug discovery. Before that, he worked at Eli Lilly, where his responsibilities ranged from leading the company’s effort in structural biology and computational chemistry to managing Lilly’s statistics departments.

Before joining INCAPS, Caviston worked at BD Biosciences, Corning Life Sciences, Roche Diagnostics Applied Science Group and Children’s Hospital Boston.


Samraat Raha, former vice president of GE Healthcare’s CodeLink microarray product line, has joined Agilent Technologies’ life science and chemical-analysis business unit as vice president of field operations for the Americas, according to ProteoMonitor’s sister publication, BioCommerce Week. Raha joined Amersham before the company’s acquisition by General Electric and worked there for almost two years before joining Agilent. Previously, he was chief business officer for EraGen of Madison, Wis., and prior to that, he was vice president of discovery services and bioreagents for Incyte Genomics.


Ann Reynolds has joined the board of directors of Invitrogen, the company said this week. Until 2002, she was the president of the University of Alabama at Birmingham. Prior to that, she was the chancellor of the City University of New York, and before that, chancellor of the California State University system. Reynolds holds a PhD and a master’s degree in zoology from the University of Iowa, and a bachelor’s degree in biology from Emporia State University in Kansas.

 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.